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ABSTRACT 
Objective: Although all marketed antiretrovirals (ARVs) have proven efficacy, genetic differences can result in varied effectiveness. This study was 
conducted to determine the effectiveness of different Highly Active Antiretroviral Therapy (HAART) combinations among patients attending HIV 
clinic at a Major Teaching Hospital in Ghana.  
Methods: The study was a retrospective study involving 500 patients at an HIV clinic in the Ashanti Region of Ghana.  
Results: Twelve major antiretroviral combinations for HAART were prescribed at the study center. The most prescribed drug combinations were 
AZT+3TC+EFV and AZT+3TC+NVP. The study identified that HAART, irrespective of the kind of drug combination used, was effective at increasing 
CD4 count within the first 6 mo of therapy initiation in the study population. However, the magnitude of the increases differed from combination to 
combination. All HAART combinations with zidovudine as one of the drugs resulted in higher CD4 counts compared with combinations containing 
stavudine. HAART with nevirapine also resulted in a higher CD4 count than those with efavirenz. However, efavirenz-based combinations appeared 
to be more effective in critically ill patients and patients with mean CD4+T helper cells count below 100 cell/mm3. 
Conclusion: There was significant variation in response to different HAART combination among Ghanaian HIV patients. However, there was no 
statistically significant difference in mean CD4 count between the two most predominately used HAART i. e AZT+3TC+EFV and AZT+3TC+NVP. 
More importantly, efavirenz was 
common among all HAART combinations that resulted in treatment failure. 
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INTRODUCTION 
The advent of Highly Active Antiretroviral Therapy has tremendously 
reduced HIV morbidity and mortality [1, 2]. Antiretroviral (ARV) are 
medications for the treatment of infection by retroviruses, primarily 
HIV. When such medicines, typically three or four, are acquired in 
combination, the approach is known as Highly Active Antiretroviral 
Therapy (HAART) [3]. Compared with Antiretroviral (ARV) 
monotherapy, HAART has significantly reduced treatment failures, 
suppressed viral transmission and mortality [4]. Although all 
marketed ARVs have proven efficacy, patient variability as a result of 
genetic differences in response to drug action can result in varied 
effectiveness [5]. These variations have been identified as a major 
problem which can lead to either sub-therapeutic or supratherapeutic 
treatment outcomes [6]. Pharmacokinetics of a drug can be affected by 
genetic polymorphism and can therefore lead to reduce plasma and 
tissue concentration, thereby altering the effectiveness and safety of a 
prescribed drug [7]. For example, it has been shown that there are 
variations in pharmacokinetics, efficacy and toxicity of ARVs among 
people of diverse ethnicity even at standard or recommended doses 
[8, 9]. 
There has not been any pharmacogenomics studies in Ghanaian 
population to help tailor antiretroviral drug selection for maximum 
health benefit of HIV patients. As such, the effectiveness or 
otherwise of Highly Active Antiretroviral Therapy is yet to be 
studied comprehensively in Ghana. It is very possible that due to 
genetic variation as well as some sociocultural practices, Ghanaian 
HIV patients may not be obtaining the expected benefits associated 
with HAART. CD4+T helper lymphocyte cell count has been used 
previously as a predictive measure of development and prognosis of 
AIDS especially in resource constraint settings where viral load 
studies may be difficult. We had earlier reported variation in HAART 
associated adverse effects in Ghanaian population [10]. Therefore, 
this study was conducted to determine the effectiveness of different 
HAART combinations among patients attending HIV clinic at Komfo 
Anokye Teaching Hospital. 
MATERIALS AND METHODS 
Study design 
The study was a cross-sectional, descriptive and retrospective in 
approach. The study was carried out at an HIV clinic at the Komfo 
Anokye Teaching Hospital in the Ashanti Region of Ghana. Variables 
were extracted from the patients’ folders using a data collection tool, 
and these included age, gender, level of education, occupation, marital 
status, type of combination therapy, comorbidities, as well as baseline 
CD4 counts before and 6 mo after initiation of HAART treatment.  
Inclusion criteria 
Patients with complete demographic information and documented 
usage of antiretroviral drugs for at least once at the study site. 
Patients with CD4 recorded at the start of therapy and at least 6 mo 
into therapy. 
Exclusion criteria 
Patients with incomplete medical history and records, and those 
with incomplete pre-adherence counselling therapy, referred 
patients, patients with kidney and liver co-morbidities. Patients 
without information on CD4 cells were also excluded. 
Sample size determination 
The minimum sample size was determined based on the formula 
modified by Naing et al. (2006). 
n=Z2 P (1-P)/d2. [10]. 
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Where n=sample size, Z=Z statistic for a level of confidence, P=expected 
prevalence (in proportion of one) and d=precision (in proportion of 
one). Using a Z statistic for a 95% confidence level (i.e., Z=1.96), precision 
of 5% (i.e., d=0.05) and a prevalence of 3.2% representing the 
prevalence of the disease in the Ashanti Region of Ghana [11]. 
Sampling technique 
Systematic random sampling was used to select patients’ folders for 
the study, covering the periods from 2011 to 2015. A total of one 
hundred patients were selected from each year of the study, by using 
a constant number (kth
Limitations of the study 
) to select a folder, making a total of 500 
folders for the entire five years. The folders were thoroughly 
examined using the inclusion and exclusion criteria. 
Analysis of data 
The data captured was entered into Statistical Package for Social 
Sciences (SPSS) Version 20.0, examined, cleaned and analyzed. Mean 
and standard deviation was used to describe continuous variables 
with normal distribution whiles median and interquartile rage were 
used to describe continuous variables with skewed distribution. 
Categorical variables were analyzed using chi-square test. A p-value 
less than 0.05 was used to assess the level of significance. 
Ethical consideration 
Ethical clearance (CHRPE/AP/156/16) was obtained from the 
Committee on Human Research, Publication and Ethics of the 
Kwame Nkrumah University of Science and Technology, Kumasi. 
Permission was obtained from the head of the directorate of 
Medicine at Komfo Anokye Teaching Hospital before data collection 
was started. Names and addresses of patients were not recorded to 
ensure that their identities are not exposed. Case Record Forms 
were stored in a safe place with restricted access. The computer 
used for the data entry was password protected and secured and 
only the principal investigator had access to it. Data obtained was 
used exclusively for the purposes of this study. 
One of the main limitations was the retrospective nature of the 
study. It was not possible to ensure that all patients complied 
with their treatment. This could confound the efficacy of the 
HAART in this study. The use of CD4 as a measure of efficacy 




The mean age of the patients was 39.94 y. Most of the respondents 
were females constituting 70.8 % (n=354,) as against (n=146, 29.2 
%) of males. Over 70 % of participants had been educated up to the 
Junior High School or have had no formal education at all. Seventy-
three percent described themselves as self-employed (see reference 
9 for more details).  
Drug combination types used by respondents 
Out of the 500 respondents in the study, only 12 of many possible 
combinations of ARVs were prescribed. Among the 12 combinations, 
AZT+3TC with either EFV OR NVP accounted for more than 50%. 
However, 3TC+TDF+EFV combination was also commonly used a as 
second line option (see reference 9 for further details). 
HAART combinations and CD4 
There was a significant difference between the mean CD4 count 
before initiation of therapy (159.7±118.7) and that after 6 mo of 
initiation of therapy (344.2±173.4 (p<0.001)). This suggested 
HAART, irrespective of the kind of drug combination used, was able 
to increase CD4 count within the first 6 mo of therapy initiation 
within the study population (table 1). However, the magnitude of the 
increases in CD4 cells differed significantly from combination to 
combination (table 1). 
 
Table 1: Mean CD4 count compared with the drug combination 
Variable Mean CD4 count (cells/mm3 P value )±SD 
Initial CD4 
























Data expressed as mean±SD. N=459. Paired samples T-test was used to compare initial CD4 to CD4 after 6months and One-way ANOVA followed by 
scheffe’s post hoc test was used to compare CD4 amongst the different ARV combination. *** means P ≤ 0.0001. 
 
 
Fig. 1: (a) Comparing AZT+3TC+EFV and D4T+3TC+EFV on CD4 count, **P ≤ 0.001 using unpaired test, 1(b) Comparing AZT+3TC+NVP and 
D4T+3TC+NVP on CD4 count 
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Comparing mean CD4 of various HAART combinations 
There was no statistically significant difference in CD4 count 
between the two most predominately used ARV combinations for 
HAART i. e AZT, 3TC, EFV and AZT, 3TC, NVP. Interestingly, these 
two major combinations increased the mean CD4 count significantly 
when compared to 3TC/TDF/EFV which was also highly preferred 
by prescribers as a second-line treatment option (table 2). 
 
Table 2: Comparing the mean CD4 of various HAART combination 
Combination type Combination type Mean difference 






























































-12.55529    
-62.07000                            
-47.32000 
16.34667 
All data are expressed as mean±SD (n=459), *p<0.05, using (one-way ANOVA followed by Scheffe’s post hoc test). 
 
Comparing zidovudine (AZT) based combinations to stavudine 
(D4T) base combination 
For all HAART combinations which differed only in either AZT or 
D4T; AZT combinations consistently resulted in higher mean CD4 
counts compared with D4T combinations (fig. 1a and b). This 
observation was statistically significant when AZT+3TC+EFV was 
compared to D4T+3TC+EFV but not when nevirapine (NVP) 
replaced efavirenz (EFV). It appears that AZT synergizes with EFV or 
a combination of 3TC+EFV in Ghanaian HIV patients. 
Comparing Efevirenz (EFV) based combinations to nevirapine 
(NVP) combinations 
Generally, the study showed that NVP improved patient baseline 
CD4 count across all combinations better than EFV although not 
statistically significant (fig. 2a), however in patients with CD4 
count lower than 100 cell/mm3
 
, it was evident that EFV was 
more effective in raising CD4 count better than NVP (fig. 2b). 
EFV was found in all HAART regimen associated with treatment 
failure. 
 
Fig. 2: a. Comparing HAART regimen that differed only in either efevirenz or Nevirapine for 6 mo on CD4 cell count, b. Comparing CD4 cell 
change of patients with low CD4 count (100 cell/mm3
 
) treated with either efevirenz or Nevirapine combinations for 6 consecutive months 
DISCUSSION 
This study highlighted the major HAART combinations and their 
effectiveness in Ghanaian population. The most prescribed 
combinations were AZT+3TC+EFV and AZT+3TC+NVP. This 
combination is similar to what has been reported elsewhere [12,13]. 
A study conducted in KATH also confirmed AZT+3TC+EFV was the 
most commonly prescribed HAART followed by AZT+3TC+NVP [13]. 
These combinations were in line with the recommendations of the 
National guidelines for the use of ARV in Ghana as well as WHO 
guidelines [14].  
There was a significant rise in mean CD4 count after 6 mo of 
initiation of therapy. Kr et al., (2014) also reported improvement in 
CD4 cell count within 6 mo of therapy in HIV patients as well as in 
those with HIV comorbidity [15]. It is prudent for HIV/AIDS patients 
to receive HAART regardless of adverse effects. It has been 
documented that the degree of immune restoration is dependent on 
Mensah et al. 
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the degree of immunodeficiency at the initiation of HAART 
treatment [16]. This may affect both morbidity and mortality rates 
in HIV patients.  
The mean CD4 count before initiation of therapy in this study was 
159.7 cells/mm3
A study conducted in high-income countries suggests that EFV is 
superior to NVP in achieving an undetectable viral load [24]. In this 
study, however, NVP proved to be more effective in improving CD4 
counts than EFV although not statistically significant. Again, in all 
combinations that differed only in AZT and D4T, AZT patients 
experienced significant improvement in CD4 and less adverse 
effects. Subsequently, there were low CD4 count increase and high 
adverse effects with D4T and NVP combinations. Interestingly, when 
CD4 was very low and in critically ill patients, EFV proved better 
than NVP at increasing CD4 counts. However, EFV HAART 
combination was associated with treatment failures or immunologic 
failure during HIV management. This result conflicts with earlier 
reports by Van Oosterhout et al. [25].  
. This shows that most of the diagnoses occurred after 
patients reported clinical symptoms. Several studies have reported 
that initiating HAART therapy early when CD4 count is high results in 
higher mean CD4 levels and better treatment outcomes [17, 18]. The 
most essential prognosis indicator of clinical advancement and 
survival after HAART initiation is based on CD4 count and medication 
adherence [19]. Patients with lower baseline CD4 count remain at risk 
for opportunistic infections for a substantially longer period than 
patients starting HAART at higher CD4 counts hence affecting risk for 
serious morbidity and death [20-23]. 
AZT efficacy was remarkably consistent in all the HAART 
combination. It appeared that AZT synergies with EFV but its use 
was always associated with severe anemia, which led to a change in 
the drug combination in certain instances. A prospective cohort 
study conducted by Shet et al., 2014, indicated that patients on 
zidovudine had 22 times higher risk of developing anemia compared 
to those on other regimens [26]. However, adverse drug reactions 
(ADRs) associated with the use of zidovudine is expected to increase 
because of its proven efficacy in Ghanaian HIV patients and its use in 
mother to child transmission [27].  
Contrary to the perception of drug stock out as the more important 
reason for drug change, this study found that drug toxicity was 
rather the most important reason for medication change. This is in 
line with other reports [26, 28]. It emerged from the study that 
TDF+3TC+EFV was becoming a popular treatment option and 
second line drug when drug toxicity was of major concern. However, 
a careful analysis showed that it was less efficacious at improving 
CD4 when compared to traditional options of AZT+3TC with either 
EFV or NVP within the first 6 mo of initiation of therapy.  
CONCLUSION 
There were 12 major antiretroviral combinations that were employed 
in HAART for the treatment of HIV patients in the study. All HAART 
therapy resulted in statistically significant increases in mean CD4 
counts within 6 mo of initiation of therapy. However, the magnitude of 
the increases differed from combination to combination. 
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